| Enzalutamide with standard first-line therapy in metastatic prostate cancer ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ... New England Journal of Medicine 381 (2), 121-131, 2019 | 1202 | 2019 |
| Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci FR Schumacher, AA Al Olama, SI Berndt, S Benlloch, M Ahmed, ... Nature genetics 50 (7), 928-936, 2018 | 773 | 2018 |
| Frequent loss of estrogen receptor-β expression in prostate cancer LG Horvath, SM Henshall, CS Lee, DR Head, DI Quinn, S Makela, ... Cancer research 61 (14), 5331-5335, 2001 | 419 | 2001 |
| FAK signaling in human cancer as a target for therapeutics BY Lee, P Timpson, LG Horvath, RJ Daly Pharmacology & therapeutics 146, 132-149, 2015 | 404 | 2015 |
| PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma WA Cooper, T Tran, RE Vilain, J Madore, CI Selinger, M Kohonen-Corish, ... Lung cancer 89 (2), 181-188, 2015 | 319 | 2015 |
| Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study SJ Lubner, MR Mahoney, JL Kolesar, NK LoConte, GP Kim, HC Pitot, ... Journal of Clinical Oncology 28 (21), 3491, 2010 | 314 | 2010 |
| Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction DV Conti, BF Darst, LC Moss, EJ Saunders, X Sheng, A Chou, ... Nature genetics 53 (1), 65-75, 2021 | 312 | 2021 |
| Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse SM Henshall, DEH Afar, J Hiller, LG Horvath, DI Quinn, KK Rasiah, K Gish, ... Cancer research 63 (14), 4196-4203, 2003 | 293 | 2003 |
| Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development T Bianco-Miotto, K Chiam, G Buchanan, S Jindal, TK Day, M Thomas, ... Cancer epidemiology, biomarkers & prévention 19 (10), 2611-2622, 2010 | 190 | 2010 |
| Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial SE Kasner, B Swaminathan, P Lavados, M Sharma, K Muir, R Veltkamp, ... The Lancet Neurology 17 (12), 1053-1060, 2018 | 183 | 2018 |
| Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen … L Emmett, C Yin, M Crumbaker, G Hruby, A Kneebone, R Epstein, ... Journal of Nuclear Medicine 60 (7), 950-954, 2019 | 173 | 2019 |
| Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization CI Selinger, TM Rogers, PA Russell, S O'toole, PY Yip, GM Wright, ... Modern pathology 26 (12), 1545-1553, 2013 | 171 | 2013 |
| Results of a prospective phase 2 pilot trial of 177Lu–PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response … L Emmett, M Crumbaker, B Ho, K Willowson, P Eu, L Ratnayake, ... Clinical genitourinary cancer 17 (1), 15-22, 2019 | 164 | 2019 |
| Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer Y Zeng, K Opeskin, ME Baldwin, LG Horvath, MG Achen, SA Stacker, ... Clinical cancer research 10 (15), 5137-5144, 2004 | 147 | 2004 |
| Circulating microRNAs predict biochemical recurrence in prostate cancer patients LA Selth, SL Townley, AG Bert, PD Stricker, PD Sutherland, LG Horvath, ... British journal of cancer 109 (3), 641-650, 2013 | 143 | 2013 |
| Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer HM Lin, L Castillo, KL Mahon, K Chiam, BY Lee, Q Nguyen, MJ Boyer, ... British journal of cancer 110 (10), 2462-2471, 2014 | 142 | 2014 |
| Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer SM Henshall, DEH Afar, KK Rasiah, LG Horvath, K Gish, I Caras, ... Oncogene 22 (38), 6005-6012, 2003 | 131 | 2003 |
| Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling L Zhao, BY Lee, DA Brown, MP Molloy, GM Marx, N Pavlakis, MJ Boyer, ... Cancer research 69 (19), 7696-7703, 2009 | 130 | 2009 |
| Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression LG Horvath, SM Henshall, JG Kench, JJ Turner, D Golovsky, PC Brenner, ... The Prostate 59 (3), 234-242, 2004 | 130 | 2004 |
| Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy NB Leighl, HL Shepherd, PN Butow, SJ Clarke, M McJannett, PJ Beale, ... Journal of Clinical Oncology 29 (15), 2077-2084, 2011 | 127 | 2011 |
